IP Library Granted Patent US 12,350,251
Granted Patent B2
US 12,350,251 · App. 16/461,477 · Granted Jul 8, 2025

Sexual health enhancement composition

Inventors: Beth Anne-Szkudlarek Brown (Plymouth, MN); Anthony Lemus (Villa Park, CA); Marnie L. Peterson (Jackson, WY)
Assignee: REV Pharmaceuticals, Inc.
A61K31/352A61K9/0014A61K31/198A61K31/223A61K47/10A61K47/32A61N1/327A61N1/0412A61N1/0492
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,350,251
App. No.
16/461,477
Granted
Jul 8, 2025
Kind
B2
Abstract

A topical composition and method comprising administering physiological effective amounts of at least two active components forskolin combined with one or more lubricating base components. Active components may include one or more of L-arginine free base, hydrochloride salt, ethyl ester or combinations thereof.

Claims (12)

1. A topical composition consisting essentially of physiological effective amounts of at least two active components comprising about 25 wt % of one or more of L-arginine hydrochloride salt, L-arginine ethyl ester or combinations thereof, and about 1 wt % of forskolin based on topical composition weight; combined with one or more lubricating base components.

2. The topical composition of claim 1 consisting of the physiological effective amounts of L-arginine hydrochloride salt, L-arginine ethyl ester, or combinations thereof, and forskolin in a gel comprising one or more lubricating base components.

3. The topical composition of claim 1 where in the lubricating base components comprising at least one lubricating pharmaceutically acceptable glycol.

4. The topical composition of claim 1 wherein the base components are selected from the group consisting of propylene glycol, polyethylene glycol 400 NF, butylene glycol, ethylene glycol, diethylene glycol, pentylene glycol, and a combination thereof, and wherein the base components comprise oil-in-water emulsions, water in-oil emulsions, anhydrous silicone bases, lipophilic foam bases, or transdermal cream bases.

5. The topical composition of claim 1 comprising about 75 wt % propylene glycol and about 25 wt % polyethylene glycol 400 NF based on lubricating base components weight.

6. The topical composition of claim 1 comprising greater than 75 wt % propylene glycol and less than about 25 wt % polyethylene glycol.

7. The topical composition of claim 1 comprising less than 75 wt % propylene glycol and greater than about 25 wt % polyethylene glycol.

8. The topical composition of claim 1 wherein the one or more base components comprise dermal penetration enhancers.

9. The topical composition of claim 1 wherein the dermal penetration enhancers comprise essential oils, fatty acids, or polysaccharides.

10. The topical composition of claim 1 wherein the base components are selected from glycols, oil-in-water emulsions, water-in-oil emulsions, lipophilic foams, water, anhydrous silicone base, lipophilic foam base, transdermal cream base, and mineral oils.

11. A topical composition comprising about 25 wt % of one or more of L-arginine hydrochloride salt, L-arginine ethyl ester, or combinations thereof, and about 1 wt % of forskolin based on topical composition weight; to provide one or more of the following conditions for sexual health enhancement: increased nitric oxide (NO) production, increased blood flow by creating nitric oxide, increased cAMP induced relaxation, relaxed state for stimulation, or enhanced relaxation.

12. A packaged sexual health composition comprising a single use sachet containing a topical gel composition about 25 wt % of one or more of L-arginine free base, hydrochloride salt, ethyl ester, or combinations thereof, and about 1 wt % of forskolin based on topical composition weight; wherein the gel comprises pharmaceutically acceptable additives selected from mineral oils, benzoyl peroxide, diethanolamine, monoethanolamine, triethanolamine, dioxin, parabens, phthalates, sodium lauryl sulfate, sodium laureth sulfate, tridosan, avobenzone, benzphenone, ethoxycinnamate, and PABA.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2022
From: BROWN, BETH ANNE-SZKUDLAREK; LEMUS, ANTHONY; PETERSON, MARNIE L.
To: REV PHARMACEUTICALS, INC.
Reel/Frame 058699/0754 →
CHANGE OF NAME Recorded Jan 18, 2022
From: ORENDA BIOSCIENCES, LLC
To: REV PHARMACEUTICALS, INC.
Reel/Frame 058767/0404 →
CHANGE OF NAME Recorded Jan 11, 2022
From: REV PHARMACEUTICALS, LLC
To: ORENDA BIOSCIENCES, LLC
Reel/Frame 058700/0528 →
Continuity (2)
Provisional Application 62424654 · Nov 21, 2016
Related Publication 20190343791A1 · Nov 14, 2019
References Cited (11)
US 5208031A · Kelly · 1993 [cited by applicant]
US 5595753A · Hechtman · 1997 [cited by applicant]
US 5804596A · Majeed · 1998 [cited by examiner]
US 7128930B1 · Sacks · 2006 [cited by examiner]
US 20030028169A1 · Fossel · 2003 [cited by examiner]
US 20070059266A1 · Ahmad et al. · 2007 [cited by applicant]
US 20120009283A1 · Bombardelli · 2012 [cited by examiner]
US 20140303681A1 · Khan et al. · 2014 [cited by applicant]
US 20170281581A1 · Brown et al. · 2017 [cited by applicant]
Mulhall et al. J. of Urology, 1997, vol. 158, pp. 1752-1759. [cited by examiner]
Mulhall et al. ((1997), Intracavernosal Forskolin: Role in Management of Vasculogenic impotence resistant to standard 3-agent pharmacotherapy, J. of Urology, 158, 1752-1759, (Year: 1997). [cited by examiner]